Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;6(11):e2343801.
doi: 10.1001/jamanetworkopen.2023.43801.

DOACs in Patients With Giant Coronary Artery Aneurysms After Kawasaki Disease

Kirsten B Dummer  1 , Koichi Miyata  1 , Chisato Shimizu  1 , Adriana H Tremoulet  1 , Jill Gleason  2 , John B Gordon  2 , Jane C Burns  1
Affiliations

DOACs in Patients With Giant Coronary Artery Aneurysms After Kawasaki Disease

Kirsten B Dummer et al. JAMA Netw Open. .
No abstract available

Plain language summary

This case series examines outcomes among patients with giant coronary artery aneurysms after Kawasaki disease treated with direct oral anticoagulants (DOACs).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tremoulet reported serving as a consultant for Janssen Pharmaceuticals outside the submitted work. No other disclosures were reported.

References

    1. Grande Gutierrez N, Mathew M, McCrindle BW, et al. . Hemodynamic variables in aneurysms are associated with thrombotic risk in children with Kawasaki disease. Int J Cardiol. 2019;281:15-21. doi:10.1016/j.ijcard.2019.01.092 - DOI - PMC - PubMed
    1. McCrindle BW, Rowley AH, Newburger JW, et al. ; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention . Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484 - DOI - PubMed
    1. Research Committee of the Japanese Society of Pediatric Cardiology; Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki Disease . Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int. 2014;56(2):135-158. doi:10.1111/ped.12317 - DOI - PubMed
    1. Poterucha TJ, Goldhaber SZ. Warfarin and vascular calcification. Am J Med. 2016;129(6):635.e1-635.e4. doi:10.1016/j.amjmed.2015.11.032 - DOI - PubMed
    1. Manlhiot C, Newburger JW, Low T, et al. ; International Kawasaki Disease Registry . Low-molecular-weight heparin vs warfarin for thromboprophylaxis in children with coronary artery aneurysms after Kawasaki disease: a pragmatic registry trial. Can J Cardiol. 2020;36(10):1598-1607. doi:10.1016/j.cjca.2020.01.016 - DOI - PubMed

Publication types

MeSH terms

Substances